Skip to main content
SpringerLink
Log in

Fludarabine phosphate

A new anticancer drug with significant activity in patients with chronic lymphocytic leukemia and in patients with lymphoma

  • Review
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Fludarabine phosphate is a purine antimetabolite approved for use in the management of patients with chronic lymphocytic leukemia. Fludarabine works primarily by inhibiting DNA synthesis. The compound also possesses lymphocytotoxic activity with preferential activity toward T-lymphocytes.

Initial preclinical studies demonstrated antitumor activity with fludarabine against L1210 murine leukemia. In phase I studies, myelosuppression was identified as the dose-limiting toxicity in patients with solid tumors and fatal neurotoxicity as the dose-limiting toxicity in adult patients with acute hematologie malignancies. The recommended dose and schedule was determined to be 18–25 mg/m2/d for five days, repeated every 28 days.

Unlike preclinical studies, phase II trials showed a lack of significant effect when fludarabine was given to patients with solid tumors. However, phase II investigations have confirmed the efficacy of fludarabine in lymphoid malignancies, including non-Hodgkin's lymphoma, mycosis fungoides, prolymphocytic leukemia, and chronic lymphocytic leukemia. The place of fludarabine in the management of leukemias in children is under investigation. Early results indicate an unusual degree of antitumor activity when the agent is used in combination chemotherapy for patients with refractory disease.

Fludarabine is an effective antitumor agent in the management of lymphoid malignancies. Studies are ongoing to more completely define the role of fludarabine in these malignancies as well as in the pediatrie leukemias. Additional studies evaluating the activity of fludarabine as an immunomodulator are warranted, due to the lymphocytotoxic properties associated with this agent.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Montgomery JA, Hewson K: Nucleosides of 2-fluoroadenine. J Med Chem 12:498–504, 1969

    Google Scholar 

  2. Brockman RW, Cheng YC, Schabel FM Jr, Montgomery JA: Metabolism and chemotherapeutic activity of 9-β-D-arabinofuranosyl-2-fluoroadenme against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase. Cancer Res 40:3610–15, 1980

    Google Scholar 

  3. Plunkett W, Huang P, Gandhi V: Metabolism and action of fludarabine phosphate. Semin Oncol 17(5 Suppl 8):3–17, 1990

    Google Scholar 

  4. Giblet ER, Anderson F, Cohen B, Pollana B, Mewissen HJ: Adenosine deaminase deficiency in two patients with severely impaired immunity. Lancet 2:1067–8, 1972

    Google Scholar 

  5. Mitchell BS, Kelley WN: Purinogenic immunodeficiency diseases: Clinical features and molecular mechanisms. Ann Intern Med 92:826–32, 1980

    Google Scholar 

  6. O'Dwyer PJ, Wagner B, Leyland-Jones B, Wittes RE, Cheson BD, Hoth DF: Deoxycoformycin (Pentostatin) for lymphoid malignancies. Ann Intern Med 108:733–43, 1988

    Google Scholar 

  7. LePage GA, Khalig A, Gottlieb JA: Studies of 9-β-D-arabinofur-anosyladenine in man. Drug Metab Dispos 1:756–9, 1973

    Google Scholar 

  8. Montgomery JA: Has the well gone dry? The First Cain Memorial Award Lecture. Cancer Res 42:3911–17, 1982

    Google Scholar 

  9. Montgomery JA: Studies on the biologic activity of purine and pyrimidine analogs. Med Res Rev 2:271–308, 1982

    Google Scholar 

  10. Montgomery JA, Clayton SD, Shortnacy AT: An improved procedure for the preparation of 9-β-D-arabinofuranosyl-2-fluoroadenine. J Heterocyclic Chem 16:157–60, 1979

    Google Scholar 

  11. Noker PE, Duncan GF, El Dareer SM, Hill DL: Disposition of 9-β-D-arabinofuranosyl-2-fluoroadenine-5′-phosphate in mice and dogs. Cancer Treat Rep 67:445–56, 1983

    Google Scholar 

  12. Malspeis L, De Souza JJV, Staubus AE, Neidhart JA, Grever MR: Pharmacokinetics of 2-F-ara-AMP in man during a phase I clinical trial. Invest New Drugs 2:116, 1984

    Google Scholar 

  13. De Souza JJV, Grever M, Neidhart JA, Staubus AE, Malspeis L: Comparative pharmacokinetics and metabolism of fludarabine phosphate (NSC 312887) in man and dog. Proc Am Assoc Cancer Res 25:361, 1984.

    Google Scholar 

  14. Sirotnak FM, Chello PL, Dorick DM, Montgomery JA: Specificity of systems mediating transport of adenosine, 9-β-D-arabino-furanosyl-2-fluoroadenine, and other purine nucleoside analogues in L1210 cells. Cancer Res 43:104–9, 1983

    Google Scholar 

  15. Cheng YC, Tsou J, Brockman RW: Enzyme activity responsible for the phosphorylation of 9-β-D-arabinofuranosyl-2-fluoroadenine (F-ara-A) to F-ara-AMP in L1210 cells. Fed Proc 38:370, 1979

    Google Scholar 

  16. Krenitsky TA, Tuttle JV, Koszalka GW, Chen IS, Beacham LM, Rideout JL, Elion GB: Deoxycytidine kinase from calf thymus. J Biol Chem 251:4055–61, 1976

    Google Scholar 

  17. Brockman RW, Schabel FM Jr, Montgomery JA: Biologic activity of 9-β-D-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-β-D-arabinofuranosyladenine. Biochem Pharmacol 26:2193–6, 1977

    Google Scholar 

  18. Plunkett W, Chubb S, Alexander L, Montgomery JA: Comparison of the toxicity and metabolism of 9-β-D-arabino-furanosyl-2-fluoroadenine and 9-β-D-arabino-furanosyladenine in human lymphoblastoid cells. Cancer Res 40:2349–55, 1980

    Google Scholar 

  19. Avramis VI, Plunkett W: Metabolism and therapeutic efficacy of 9-β-D-arabinofuranosyl-2-fluoroadenine against murine leukemia P388. Cancer Res 42:2587–91, 1982

    Google Scholar 

  20. Huang P, Chubb S, Plunkett W: Termination of DNA synthesis by 9-β-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity. J Biol Chem 265:16617–25, 1990

    Google Scholar 

  21. White LE, Shaddix SC, Brockman RW, Bennett LL Jr: Comparison of the actions of 9-β-D-arabinofuranosyl-2-fluoroadenine and 9-β-arabinofuranosyladenine on target enzymes from mouse tumor cells. Cancer Res 42:2260–4, 1982

    Google Scholar 

  22. White L, Shaddix SC, Cheng YC, Brockman RW, Bennett LL Jr: Inhibition of ribonucleotide reductase and DNA polymerases of tumor cells by 9-β-D-arabinofuranosyl-2-fluoroadenine-5′-triphosphate (2-F-ara-ATP). Proc Am Assoc Cancer Res 22:33, 1981

    Google Scholar 

  23. Tseng WC, Derse D, Cheng YC, Brockman RW, Bennett LL Jr: “Self-potentiation” mechanism of action of 9-β-D-arabinofur-anosyl-2-fluoroadenine. Fed Proc 40:666, 1981

    Google Scholar 

  24. Tseng WC, Derse D, Cheng YC, Brockman RW, Bennett LL Jr:in vitro biological activity of 9-β-D-arabinofuranosyl-2-fluoro-adenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. Mol Pharmacol 21:474–7, 1982

    Google Scholar 

  25. Plunkett W, Chubb S: Toxicity, metabolism and incorporation into DNA and RNA of arabinosyl-2-fluoroadenine (F-ara-A). Proc Am Assoc Cancer Res 26:19, 1985

    Google Scholar 

  26. Catapano CV, Chandler KB, Fernandex DJ: Effects of anticancer agents on primer RNA formation in human leukemia cells. Proc Am Assoc Cancer Res 31:420, 1990

    Google Scholar 

  27. Avramis VI: Pharmacodynamics and proposed mechanism of therapeutic action and host toxicity of 9-β-D-arabinofuranosyl-2-fluoroadenine monophosphate (7-araAMP) in P388 murine leukemia-bearing mice. Cancer Invest 7:129–37, 1989

    Google Scholar 

  28. Avramis VI, Plunkett W: 2-Fluoro-ATP: A toxic metabolite of 9-β-D-arabinofuranosyl-2-fluoroadenine (F-araA). Biophys Biochem Res Comm 113:35–43, 1983

    Google Scholar 

  29. Spriggs D, Robbins G, Mitchell T, Kufe D: Incorporation of 9-β-D-arabinofuranosyl-2-fluoroadenine into HL60 cellular RNA and DNA. Biochem Pharmacol 35:247–52, 1986

    Google Scholar 

  30. Huang P, Plunkett W: Preferential incorporation of arabinofur-anosyl-2-fluoroadenine (F-ara-A) into poly (A+) RNA and its inhibitory effects on transcription and translation. Proc Am Assoc Cancer Res 27:21, 1986

    Google Scholar 

  31. Huang MC, Hatfield K, Roetker AW, Montgomery JA, Blakley RL: Analogs of 2′-deoxyadenosine: Facile enzymatic preparation and growth inhibitory effects on human cell lines. Biochem Pharmacol 30:2663–71, 1981

    Google Scholar 

  32. Verhoef VL, Fridland A: Differential sensitivity of human T- and B-lymphoblasts to cytotoxic nucleoside analogues. In: Chabner Bruce A (ed) Rational Basis for Chemotherapy. (UCLA Symposium on Molecular and Cellular Biology. New Series. Volume 4.) Alan R. Liss, Inc., New York, 1983, pp 261–73

    Google Scholar 

  33. Boldt DH, Von Hoff DD, Kuhn JG, Hersh M: Effects on human peripheral lymphocytes ofin-vivo administration of 9-β-D-arabinofuranosyl-2-fluoroadenine-5′-monophosphate (NSC-312887), a new purine antimetabolite. Cancer Res 44:4661–6, 1984

    Google Scholar 

  34. Lathan B, Diehl V, Clark GM, Von Hoff DD: Cytotoxic activity of 9-β-D-arabinofuranosyl-2-fluoroadenine 5-monophosphate (fludarabine, NSC-312887) in a human tumor cloning system. Eur J Cancer Clin Oncol 24:1891–5, 1988

    Google Scholar 

  35. Grever MR, Leiby J, Kraut E, Metz E, Neidhart J, Balcerzak S, Malspeis L: A comprehensive phase I and II clinical investigation of fludarabine phosphate. Semin Oncol 17 (Suppl 8):39–48, 1990

    Google Scholar 

  36. Hutton JJ, Von Hoff DD, Kuhn J, Phillips J, Hersh M, Clark G: Phase I clinical investigation of 9-β-D-arabinofuranosyl-2-fluoroadenine 5-monophosphate (NSC 312887), a new purineantimetabolite. Cancer Res 44:4183–6, 1984

    Google Scholar 

  37. Casper ES, Mittleman A, Kelson D, Young CW: Phase I clinical trial of fludarabine phosphate (F-ara-AMP). Cancer Chemother Pharmacol 15:233–5, 1985

    Google Scholar 

  38. Kavanagh JJ, Krakoff IH, Bodey GP: Phase I study of fludarabine (2-fluoro-ara-AMO). Eur J Cancer Clin Oncol 21:1009–11, 1985

    Google Scholar 

  39. Leiby JM, Grever MR, Staubus AE, Neidhart JA, Malspeis L: Phase I clinical investigation of fludarabine phosphate by a loading dose and continuous-infusion schedule. J Natl Cancer Inst 80:447–9, 1988

    Google Scholar 

  40. Grever MR, Leiby JM, Kraut EH, Neidhart JA, Malspeis L, Balcerzak SP: A phase I investigation of 2-fluoro-araAMP in refractory leukemia. Blood 64:165A, 1984

    Google Scholar 

  41. Warrell RP Jr, Berman E: Phase I and II study of fludarabine phosphate in leukemia: Therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol 4:74–9, 1986

    Google Scholar 

  42. Spriggs DR, Stopa E, Mayer RJ, Schoene W, Kufe DW: Fludarabine phosphate (NSC 312887) infusions for the treatment of acute leukemia: Phase I and neuropathological study. Cancer Res 46:5953–8, 1986

    Google Scholar 

  43. Avramis VI, Champagne J, Sato J, Krailo M, Ettinger LJ, Poplack DG, Finkelstein J, Reaman G, Hammond GD, Holcenberg JS: Pharmacology of fludarabine phosphate after a phase I/II trial by a loading bolus and continuous infusion in pediatrie patients. Cancer Res 50:7226–31, 1990

    Google Scholar 

  44. Avramis VI, Wierzma S, Holcenberg JS, Reaman G, Hammond D, Sato J: Clinical pharmacology of fludarabine phosphate (F-ara-AMP) followed by cytosine arabinoside in pediatrie patients with relapsed leukemia. (Abstract) Proc Annu Meet Am Soc Clin Oncol 10:A359, 1991

    Google Scholar 

  45. Sato JK, Wiersma S, Krailo M, Bostrom B, Shurin S, Cheerva A, Hammond D, Avramis V: Phase I clinical and pharmacodynamic study of continuous infusion (CI) fludarabine followed by CI cytosine arabinoside (ara-C) in relapsed leukemia. (Abstract) Proc annu Meet Am Assoc Cancer Res 33:A1266, 1992

    Google Scholar 

  46. Hersch MR, Kuhn JG, Phillips JL, Clark G, Ludden TM, Von Hoff DD: Pharmacokinetic study of fludarabine phosphate (NSC 312887). Cancer Chemother Pharmacol 17:277–80, 1986

    Google Scholar 

  47. DeSouza JJV, Leiby JM, Staubus AE, Grever MR, Malspeis L: Altered pharmacokinetics of fludarabine phosphate (F) by 2′-deoxycoformycin (DCF) in the dog and analysis of a route of fludarabine activation. Proc Am Assoc Cancer Res 26:358, 1985

    Google Scholar 

  48. Weiss GB, Metch B, Von Hoff DD, Taylor SA, Saiers JH: Phase II trial of fludarabine phosphate in patients with head and neck cancer: A Southwest Oncology Group study. Cancer Treat Rep 71:1313–14, 1987

    Google Scholar 

  49. Mittelman A, Savona S, Puccio C, Chun H, Ahmed T, Feldman E, Sullivan P, Arnold P, Arlin Z: Phase II trial of fludarabine phosphate (F-Ara-AMP) in patients with advanced head and neck cancer. Invest New Drugs 8:S65–7, 1990

    Google Scholar 

  50. Taylor SA, Crowley J, Vogel FS, Townsend JJ, Eyre HJ, Jaeckle KA, Hynes HE, Guy JT: Phase II evaluation of fludarabine phosphate in patients with central nervous system tumors. A Southwest Oncology Group trial. Invest New Drugs 9:195–7, 1991

    Google Scholar 

  51. Taylor SA, Eyre HJ: Randomized phase II trials of acivicin (AT-125, NSC 163501) and fludarabine (2-fluoro-ara-AMP, NSC 312887) (2FLAMP) in recurrent malignant gliomas: A SWOG study. Proc Am Assoc Clin Oncol 6:71, 1987

    Google Scholar 

  52. Cascino TL, Brown LD, Morton RF, Everson LK, Marschke RF, Dinapoli RP, O'Fallon JR: Evaluation of fludarabine phosphate in patients with recurrent glioma. Am J Clin Oncol 11:586–8, 1988

    Google Scholar 

  53. Carpenter JT Jr, Vogel CL, Wang G, Raney M: Phase II evaluation of fludarabine in patients with metastatic breast cancer: A Southeastern Cancer Study Group trial. Cancer Treat Rep 70:1235–6, 1986

    Google Scholar 

  54. Mittelman A, Ashikari R, Ahmed T, Savona S, Arnold P, Arlin Z: Phase II trial of fludarabine phosphate (F-araAMP) in patients with advanced breast cancer. Cancer Chemother Pharmacol 22:63–4, 1988

    Google Scholar 

  55. Ajani JA, Abbruzzese JL, Faintuch JS, Blackburn R, Levin B, Bowman BM: Phase II study of fludarabine phosphate in patients with advanced colorectal carcinoma. Invest New Drugs 6:47–50, 1988

    Google Scholar 

  56. Harvey WH, Fleming TR, Von Hoff DD, Katterhagen JG, Coltman CA Jr: Phase II study of fludarabine phosphate in previously untreated patients with colorectal carcinoma. A Southwest Oncology Group study. Cancer Treat Rep 71:1319–20, 1987

    Google Scholar 

  57. Harvey WH, Fleming TR, Beltran G, Saiers JH, Oishi N, Von Hoff DD: Phase II study of fludarabine phosphate in previously untreated patients with hepatoma: A South-west Oncology Group study. Cancer Treat Rep 71:1111–12, 1987

    Google Scholar 

  58. Weiss GR, Crowley J, Von Hoff DD, Taylor SA, Belt RJ, Coltman CA Jr, Hynes HE, Costanzi JJ: Phase II study of fludarabine phosphate for the treatment of advanced non-small cell carcinoma of the lung: A Southwest Oncology Group study. Cancer Treat Rep 70:1123–4, 1986

    Google Scholar 

  59. Rainey JM, Hill JB, Crowley J: Evaluation of fludarabine in small cell carcinoma: A Southwest Oncology Group study. Invest New Drugs 6:45–6, 1988

    Google Scholar 

  60. Kavanagh JJ, Stringer CA, Copeland LJ, Gershenson DM, Saul P: Phase II trial of fludarabine in patients with epithelial ovarian cancer. Cancer Treat Rep 70:425–6, 1986

    Google Scholar 

  61. Von Hoff DD, Kronmal R, O'Toole RV, Surwit EA, Hutton JJ, Alberts DS: Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced ovarian cancer: A Southwest Oncology Group study. Am J Clin Oncol 11:146–8, 1988

    Google Scholar 

  62. Von Hoff DD, Green S, Alberts DS, Stock-Novack DL, Surwit EA, Miller TP, Stephens RL: Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced endometrial cancer. A Southwest Oncology Group study. Am J Clin Oncol 14:193–4, 1991

    Google Scholar 

  63. Von Hoff DD, Green S, Surwit EA, Hannigan EV, Alberts DS: Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced cervical cancer. A Southwest Oncology Group study. Am J Clin Oncol 13:433–5, 1990

    Google Scholar 

  64. Kilton L, Benson A, Greenburg A, Johnson P, Shapiro C, Shiomoto G, Blough R, Weidner L: Phase II trial of fludarabine phosphate (FAMP) in adenocarcinoma of the pancreas: An Illinois Cancer Council study. Proc Am Soc Clin Oncol 7:103, 1988

    Google Scholar 

  65. Balducci L, Blumenstein B, Von Hoff DD, Davis M, Hynes HE, Bukowsky RM, Crawford ED: Evaluation of fludarabine phosphate in renal cell carcinoma: A South-west Oncology Group study. Cancer Treat Rep 71:543–4, 1987

    Google Scholar 

  66. Shevrin DH, Lad TE, Kilton LJ, Cobleigh MA, Vogelzang NJ, Blough RR, Weidner LL: Phase II trial of fludarabine phosphate in advanced renal cell cancer: An Illinois Cancer Council study. Invest New Drugs 7:251–3, 1989

    Google Scholar 

  67. Pazdur R, Samson MK, Baker LH: Fludarabine phosphate: Phase II evaluation in advanced soft-tissue sarcomas. Am J Clin Oncol 10:341–3, 1987

    Google Scholar 

  68. Kish JA, Kopecky K, Samson MK, Von Hoff DD, Fletcher WS, Kempf RA, Muggia FM: Evaluation of fludarabine phosphate in malignant melanoma. A South-west Oncology Group study. Invest New Drugs 9:105–8, 1991

    Google Scholar 

  69. Leiby JM, Snider KM, Kraut EH, Metz EN, Malpeis L, Grever MR: Phase II trial of 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate in non-Hodgkin's lymphoma: Prospective comparison of response with deoxycytidine kinase activity. Cancer Res 47:2719–22, 1987

    Google Scholar 

  70. Redman J, Cabanillas F, Velazquez W, McLaughlin P, Hagemeister F, Swan F, Rodriguez M, Plunkett W, Keating M: Phase II trial of fludarabine phosphate in lymphoma: An effective new agent in low grade lymphoma. J Clin Oncol 10:790–4, 1992

    Google Scholar 

  71. Whelan JS, Davis CL, Rule S, Ranson M, Smith OP, Mehta AV, Catovsky D, Rohatiner AZS, Lister TA: Fludarabine phosphate for the treatment of low grade lymphoid malignancy. Br J Cancer 64:120–3, 1991

    Google Scholar 

  72. Hochster H, Cassileth P: Fludarabine phosphate therapy of non-Hodgkin's lymphoma. Semin Oncol 17 (Suppl 8):63–5, 1990

    Google Scholar 

  73. Von Hoff DD, Dahlberg S, Hartstock RJ, Eyre HJ: Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: A Southwest Oncology Group study. J Natl Cancer Inst 82:1353–5, 1990

    Google Scholar 

  74. Kraut EH, Crowley JJ, Grever MR, Keppen MD, Bonnet JD, Hynes HE, Salmon SE: Phase II study of fludarabine phosphate in multiple myeloma. Invest New Drugs 8:199–200, 1990

    Google Scholar 

  75. Kantarjian HM, Alexanian R, Koller CA, Kurzrock R, Keating MJ: Fludarabine therapy in macroglobulinemic lymphoma. Blood 75:1928–31, 1990

    Google Scholar 

  76. Dimopoulos MA, O'Brien Susan, Kantarjian H, Pierce S, DeLasalle K, Barlogie B, Alexanian R, Keating MJ: Fludarabine therapy in Waldenstr<ouml>m's macroglobulinemia. Am J Med 95:49–52, 1993

    Google Scholar 

  77. Kantarjian HM, Schachner J, Keating MJ: Fludarabine therapy in hairy cell leukemia. Cancer 67:1291–3, 1991

    Google Scholar 

  78. Grever MR, Coltman CA Jr, Files JC, Greenberg BR, Hutton JJ, Talley RL, Von Hoff DD, Balcerzak SP: Fludarabine monophosphate in chronic lymphocytic leukemia. Blood 68:223a, 1986

    Google Scholar 

  79. Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B, Velasquez W, Plunkett W, Freireich EJ, McCredie KB: Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 74:19–25, 1989

    Google Scholar 

  80. Cheson BD, Bennett JM, Rai KR, Grever MR, Kay NE, Schiffer CA, Oken MM, Keating MJ, Boldt DH, Kempin SJ, Foon KA: Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute-Sponsored Working Group. Am J Hematol 29:152–63, 1988

    Google Scholar 

  81. Mittelman A, Lichtman S, Budman D, Silver R, Savona S, Chun H, Puccio C, Ahmed T, Arnold P, Arlin Z: Therapy of chronic lymphocytic leukemia (CLL) with fludarabine phosphate (FAMP). Blood 72:250a, 1988

    Google Scholar 

  82. Puccio CA, Mittelman A, Lichtman SM, Silver RT, Budman DR, Ahmed T, Feldman EJ, Coleman M, Arnold PM, Arlin ZA, Chun HG: A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia. J Clin Oncol 9:1562–9, 1991

    Google Scholar 

  83. Hiddemann W, Rottmann R, Vormann B, Thiel A, Essink M, Ottensmeier C, Freund M, Buchner T, van de Loo J: Treatment of advanced chronic lymphocytic leukemia by fludarabine: Results of a clinical phase-II study. Ann Hematol 63:1–4, 1991

    Google Scholar 

  84. Keating MJ, Kantarjian H, Talpaz M, Koller C, Redman J, McCredie KB: Fludarabine — Results of therapy in previously treated (PT) and untreated (UNT) chronic lymphocytic leukemia (CLL). Blood 72:207a, 1988

    Google Scholar 

  85. Keating MJ, O'Brien S, Kantarjian H, Koller C, Freireich EJ, McCredie KB: High response rate with fludarabine ± prednisone in untreated chronic lymphocytic leukemia. Blood 74:159a, 1989

    Google Scholar 

  86. Kantarjian HM, Childs C, O'Brien S, Huh Y, Miloslav B, Schachner J, Koller C, Keating MJ: Efficacy of flud-→abine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia. Am J Med 90:223–8, 1991

    Google Scholar 

  87. Buchanan JG: Treatment of chronic lymphocytic leukemia. N Engl J Med 93:55–8, 1981

    Google Scholar 

  88. Foon KA, Gale RP: Chronic lymphocytic leukemia. In: Gale RP (ed) Leukemia Therapy. Boston, 1986, pp 165–80

  89. Cheson BD: Current approaches to the chemotherapy of B-cell chronic lymphocytic leukemia: A review. Am J Hematol 32:72–7, 1989

    Google Scholar 

  90. Chun HG, Leyland-Jones BR, Caryk SM, Hoth DF: Central nervous system toxicity of fludarabine phosphate. Cancer Treat Rep 70:1225–8, 1986

    Google Scholar 

  91. Merkel DE, Griffen NL, Kagan-Hallet K, Von Hoff DD: Central nervous system toxicity with fludarabine. Cancer Treat Rep 70:1449–50, 1986

    Google Scholar 

  92. Cohen RB, Abdallah JM, Gray JR, Foss F: Reversible neurologic toxicity in patients treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia. Ann Intern Med 118:114–116, 1993

    Google Scholar 

  93. Phillis JW, Kostopoulus GK, Edstrom JP, Ellis SW: Role of adenosine and adenine nucleotides in central nervous function. In: Baer HP, Drummond GI (eds) Physiological and Regulatory Functions of Adenosine and Adenine Nucleotides. New York, Raven Press, 1979, pp 343–59

    Google Scholar 

  94. Havlica I, Ababei L, Branisteanu D, Topoliceanu F: Preliminary data on the possible hypnogenic role of adenosine. Neurochemistry 21:1019–20, 1973

    Google Scholar 

  95. Snyder FF, Lukey T: Kinetic considerations for the regulation of adenosine and deoxyadenosine metabolism in mouse and human tissues based on a thymocyte model. Biochem Biophys Acta 696:299–307, 1982

    Google Scholar 

  96. Hurst PG, Haviv MD, Garewal H, Bluestein M, Paquin M, Greenberg BR: Pulmonary toxicity associated with fludarabine phosphate. Invest New Drugs 5:207–10, 1987

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medicine/Oncology, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, 78284-7884, San Antonio, Texas, USA

    Gladys Rodriguez

Authors
  1. Gladys Rodriguez
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rodriguez, G. Fludarabine phosphate. Invest New Drugs 12, 75–92 (1994). https://doi.org/10.1007/BF00874436

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00874436

Key words

Search

Navigation